FGFR2 and breast carcinoma: The authors also carried out an analysis of the METABRIC (Molecular Taxonomy of Breast Cancer) dataset [9] and found a 1.8% rate of FGFR2 amplification in breast cancer, associated with a poorer prognosis and resistance to endocrine therapy [63].